Latest Breaking News On - Ashleigh barreto - Page 2 : comparemela.com

Viracta Therapeutics to Host R&D Day on October 4, 2023

Viracta Therapeutics to Host R&D Day on October 4, 2023
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Roberta baiocchiPierluigi porcuAshleigh barretoDevelopment rd day onOhio state universityHead of investor relations corporate communicationsViracta therapeutics incDivision of hematologyDivision of hematologic malignanciesHost rd dayKey opinion leadersMedical oncologyHematologic malignanciesHematopoietic stem cell transplantationThomas jeffersonInternal medicine

Viracta Therapeutics Announces New Employment Inducement Grant

Viracta Therapeutics Announces New Employment Inducement Grant
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Ashleigh barretoDarrelp cohenCompensation committee of viracta board directorsHead of investor relations corporate communicationsViracta therapeutics incChief medical officerCompensation committeeEquity incentiveEquity incentive planInducement planNasdaq listing ruleViracta therapeuticsRelations contactInvestor relations

Viracta Therapeutics Announces New Employment Inducement Grant - Viracta Therapeutics (NASDAQ:VIRX)

SAN DIEGO, Aug. 18, 2023 (GLOBE NEWSWIRE) Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact

Ashleigh barretoDarrelp cohenCompensation committee of viracta board directorsViracta therapeutics incHead of investor relations corporate communicationsChief medical officerCompensation committeeEquity incentiveEquity incentive planInducement planNasdaq listing ruleViracta therapeuticsRelations contactInvestor relations

Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphoma

Results from Phase 1b/2 trial showed complete responses achieved and ongoing durable responses observed out to approximately 36 months across multiple EBV+ lymphoma subtypes, including some of the.

United statesKathy vincentDarrelp cohenAshleigh barretoPierluigi porcuGlobenewswire incHead of investor relations corporate communicationsDivision of hematologic malignanciesViracta therapeutics incDepartment of medical oncologyGreig communicationsAmerican society of hematologyThomas jefferson universityMedical oncologyHematologic malignanciesHematopoietic stem cell transplantation

Viracta Therapeutics Appoints Darrel P Cohen, M D , Ph D as Chief Medical Officer

SAN DIEGO, Aug. 07, 2023 Viracta Therapeutics, Inc. , a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients.

Ashleigh barretoDarrelp cohenMark rotheraKathy vincentViracta therapeutics incGreig communicationsGeorgetown university medical centerBiosight pharmaceuticalsPhase clinical development at pfizer oncologyLeadership teamHead of clinical developmentGlobenewswire incDuke university medical centerCell therapy at athenex incHead of investor relations corporate communicationsBoston university school of medicine